Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 28;10(3):e24831.
doi: 10.2196/24831.

Overview of Graves Ophthalmopathy Literature From 1999 to 2019: Bibliometric Analysis

Jiamin Cao  1 , Nuo Wang  1 , Shiying Hou  2 , Xin Qi  2 , Yu Chen  1 , Wei Xiong  1
Affiliations

Overview of Graves Ophthalmopathy Literature From 1999 to 2019: Bibliometric Analysis

Jiamin Cao et al. Interact J Med Res. .

Abstract

Background: Research on Graves ophthalmopathy has increased remarkably over the last 2 decades; however, few statistical analyses of the data presented in these publications have been conducted.

Objective: This study aims to detect and analyze emerging trends and collaboration networks in Graves ophthalmopathy research.

Methods: Graves ophthalmopathy-related publications from 1999 to 2019 were collected from the Web of Science Core Collection Database. Collected publications were restricted by category (article or review) and language (English). Bibliometric analyses included changes in the annual numbers of publications, journals, authors, countries, institutions, keywords, and references.

Results: In total, 3051 publications that met the criteria were collected. The number of annual publications has exhibited an increasing trend over the last 20 years. The journal Thyroid ranked first, publishing 183 Graves ophthalmopathy-related studies. There was no evidence of a relationship between impact factor (IF) and the number of publications (P=.69). The author Smith TJ had the largest number of publications on Graves ophthalmopathy (n=83). Of the countries that had published Graves ophthalmopathy-related articles, the United States had the largest number (n=784) and the highest centrality (0.18). Among institutions, the University of Pisa (Italy) contributed the most Graves ophthalmopathy-related articles (n=114). The most recent burst keywords (proliferation, rituximab, and selenium) and references may provide clues on emerging trends in research and clinical practice.

Conclusions: This bibliometric analysis highlights countries, institutions, and authors who contributed to Graves ophthalmopathy-related publications. Emerging trends in Graves ophthalmopathy research, based on burst keywords and references, may provide clues relevant to clinical practice and future research.

Keywords: CiteSpace; Graves ophthalmopathy; Web of Science; bibliometric analysis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Number of Graves ophthalmology–related publications from 1999 to 2019.
Figure 2
Figure 2
Network of co-operation relationships among authors generated using CiteSpace.
Figure 3
Figure 3
Annual publications distributed according to country.
Figure 4
Figure 4
Network of co-operation among countries generated using the CiteSpace web-based analysis platform.
Figure 5
Figure 5
Institution co-operation network.
Figure 6
Figure 6
Keywords network.
Figure 7
Figure 7
Top 30 strongest burst keywords.
Figure 8
Figure 8
Reference network.
Figure 9
Figure 9
Top 30 strongest references.
See this image and copyright information in PMC

References

    1. Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552–65. doi: 10.1056/NEJMra1510030. - DOI - PubMed
    1. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996 Mar;121(3):284–90. doi: 10.1016/s0002-9394(14)70276-4.S0002-9394(14)70276-4 - DOI - PubMed
    1. Smith T, Janssen J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019 Feb 01;40(1):236–67. doi: 10.1210/er.2018-00066. http://europepmc.org/abstract/MED/30215690 5094009 - DOI - PMC - PubMed
    1. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves' Orbitopathy (EUGOGO) The 2016 European Thyroid Association/European Group on graves' orbitopathy guidelines for the management of graves' orbitopathy. Eur Thyroid J. 2016 Mar;5(1):9–26. doi: 10.1159/000443828. https://www.karger.com?DOI=10.1159/000443828 etj-0005-0009 - DOI - PMC - PubMed
    1. Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye (Lond) 2019 Feb;33(2):183–90. doi: 10.1038/s41433-018-0321-y. http://europepmc.org/abstract/MED/30575804 10.1038/s41433-018-0321-y - DOI - PMC - PubMed